Antibodies to CEA, an oncofetal glycoprotein commonly measured as a tumor marker, may be found in 46–56% of gastrointestinal tumors, especially in cancer at an early stage, even with undetectable circulating CEA [7,106]. This evidence concerns the gene CEACAM5 and digestive system neoplasm.